8-K: Polomar Health Amends Distribution Deal, Sets Revenue Targets

Polomar Health Services, Inc. has amended its product fulfillment and distribution agreement with ForHumanity, Inc., extending exclusivity and establishing new revenue milestones and payment schedules.

Summary

• Polomar Health Services, Inc. (PMHS) executed a Second Amendment to its Amended and Restated Product Fulfillment and Distribution Agreement with ForHumanity, Inc. (FHH) and Island Group 40, LLC (IG4), effective December 5, 2025.
• The agreement establishes FHH as the exclusive partner for Dry Inhalables through June 30, 2026, in exchange for a product purchase guarantee of not less than $750,000.
• Exclusivity can be extended through December 31, 2026, if PMHS receives $1,750,000 in revenues from FHH by June 30, 2026.
• Further exclusivity can be extended through June 30, 2027, if PMHS receives $5,000,000 in revenues from FHH for the calendar year ending December 31, 2026.
• Subsequent extensions are tied to escalating revenue targets: $6,000,000 for Jan-Jun 2027 (or $8,000,000 if a third product is launched by June 2026) for exclusivity through Dec 31, 2027; and $15,000,000 for fiscal year 2027 (or $20,000,000 if a third product is launched by June 2027) for exclusivity through Dec 31, 2028.
• Perpetual exclusivity is granted upon reaching $50,000,000 in annual sales, with annual exclusivity goals increasing by 30% over the prior year until that threshold is met.
• PMHS may terminate the agreement with 90 days' written notice if average monthly gross revenues from FHH are less than $100,000 per month commencing January 1, 2025, through July 30, 2026.
• The schedule for remaining guaranteed payments has been modified: $100,000 due December 8, 2025 (acknowledged as received), $200,000 due December 29, 2025, and $200,000 due January 12, 2026, totaling $500,000.
• PMHS acknowledges receipt of $350,000 of the total $750,000 in guaranteed payments due under the Amended Agreement, inclusive of the $100,000 payment due December 8, 2025.
• New provisions include FHH providing 12-month sales forecasts within 90 days of sales commencement, updated quarterly, and notifying PMHS of material deviations (+/10%) within five business days.
• Both parties are required to maintain minimum general liability insurance of $2,000,000 aggregate and $1,000,000 per occurrence, with Polomar Specialty Pharmacy, LLC also maintaining $3,000,000 aggregate product liability insurance, with coverage increasing proportionally to sales milestones.
• In the event of bankruptcy or change of control, PMHS will take reasonable steps to ensure FHH can continue to purchase or manufacture products by providing necessary formulation and manufacturing instructions.

Sentiment

Score: 6

Explanation: The agreement provides a structured framework for future revenue generation and partnership, with clear milestones and payment schedules. However, the ambitious revenue targets and the discrepancy in guaranteed payment figures introduce some uncertainty. The risks associated with patent grants and market adoption are also noted.

Positives

• Secures a clear framework for future revenue generation and partnership stability through defined exclusivity milestones with ForHumanity, Inc.
• Establishes specific, escalating revenue targets ($1,750,000 by June 30, 2026; $5,000,000 for calendar year 2026; $6,000,000 for Jan-Jun 2027; $15,000,000 for fiscal year 2027) that, if met, extend the distribution agreement.
• Provides for a mechanism to achieve perpetual exclusivity for ForHumanity upon reaching $50,000,000 in annual sales, indicating significant long-term potential for product sales.
• Guaranteed payments totaling $750,000 are structured, with $350,000 already received and $400,000 scheduled for December 2025 and January 2026 (based on the $750,000 total less $350,000 received).
• The agreement includes a termination clause for PMHS if minimum average monthly sales targets are not met, providing an exit strategy if the partnership underperforms.
• Improved communication protocols are established, clarifying roles for direct-to-consumer (DTC) and business-to-business (B2B) sales.
• Mandatory sales forecasts from ForHumanity will aid Polomar in managing product availability and supply.
• Provisions for increased insurance coverage tied to sales milestones enhance risk management as the business grows.

Negatives

• The filing contains a discrepancy regarding the total guaranteed payments and the sum of the remaining scheduled payments. The filing states total guaranteed payments are $750,000, with $350,000 already received, implying $400,000 remaining. However, the schedule for remaining payments totals $500,000 ($100,000 on Dec 8, 2025; $200,000 on Dec 29, 2025; $200,000 on Jan 12, 2026).
• The termination clause for PMHS is based on average monthly gross revenues less than $100,000 per month commencing January 1, 2025, through July 30, 2026, which includes a period already passed, potentially limiting its immediate applicability or creating ambiguity.
• The exclusivity milestones require significant revenue generation from ForHumanity ($1,750,000 by June 30, 2026; $5,000,000 for calendar year 2026; $6,000,000 for Jan-Jun 2027; $15,000,000 for fiscal year 2027) which may be challenging to achieve.
• The ability for ForHumanity to 'cure' missed exclusivity milestones by purchasing up to 10% of the milestone amount could allow them to maintain exclusivity without fully meeting sales targets.

Risks

• The previously licensed intellectual property may not be granted the pending patents.
• ForHumanity's ability to effectively market the licensed medications to increase customer value and financial returns is uncertain.
• The ability to integrate the ForHumanity telemedicine network into the existing Polomar business and realize the benefits of the Agreement is not guaranteed.
• Other general risks described under the headings 'Risk Factors' and 'Cautionary Statement Concerning Forward-Looking Statements' in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other periodic filings with the SEC.

Future Outlook

The agreement outlines a clear path for potential long-term revenue growth and partnership exclusivity, contingent on ForHumanity meeting escalating sales targets for Polomar's Dry Inhalables. The company anticipates realizing benefits from integrating ForHumanity's telemedicine network, though this is subject to various risks including patent grants and market adoption.

Management Comments

• "Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results or performance of each company to be materially different from any future results or performance expressed or implied by such forward-looking statements."
• "You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are not guarantees of future performance, and actual results, developments, and business decisions may differ from those envisaged by our forward-looking statements."
• "Except as required by law, we undertake no obligation to update such statements to reflect events or circumstances arising after the date of this press release, and we caution investors not to place undue reliance on any such forward-looking statements."

Industry Context

This agreement positions Polomar Health Services within the growing market for specialized pharmaceutical distribution, particularly for 'Dry Inhalables.' The integration of a telemedicine network (ForHumanity) suggests a strategy to leverage digital health platforms for broader market reach, aligning with trends in direct-to-consumer healthcare and remote patient care. The focus on specific medications like sildenafil and eletriptan indicates a niche market strategy within respiratory and potentially other therapeutic areas.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.
• The revenue milestones, such as $50,000,000 for perpetual exclusivity, are specific to this partnership and cannot be directly compared without detailed industry-specific sales data for similar dry inhalable products or distribution agreements.
• The insurance coverage requirements ($2,000,000 general liability, $3,000,000 product liability) are standard for pharmaceutical distribution, with the scaling clause reflecting good practice for growing enterprises.

Stakeholder Impact

• Shareholders: Potential for increased revenue and long-term partnership stability if ForHumanity meets sales targets, but also exposure to risks related to market adoption and patenting. The discrepancy in payment figures could be a point of concern.
• Employees: Stable or growing business operations if the partnership is successful, potentially leading to job security or expansion.
• Customers (of ForHumanity): Continued access to Dry Inhalables through an exclusive distribution channel.
• Suppliers: Potential for increased demand for raw materials and manufacturing services if product sales grow.
• Creditors: Improved financial stability if guaranteed payments and revenue milestones are met, enhancing the company's ability to meet its obligations.

Next Steps

• ForHumanity to provide a 12-month sales forecast within 90 days of sales commencement.
• ForHumanity to provide updated sales forecasts quarterly by the fifth business day of the month.
• ForHumanity to notify Polomar within five business days of any material deviation (+/10%) from sales forecasts.
• Polomar Health Services to receive remaining guaranteed payments of $200,000 by December 29, 2025, and $200,000 by January 12, 2026.
• Achievement of revenue milestones ($1,750,000 by June 30, 2026; $5,000,000 for calendar year 2026, etc.) to extend exclusivity.
• Parties to increase insurance coverage as sales milestones are met.

Key Dates

Recommendation

The amendment provides a structured framework for future revenue and partnership, which is a positive. However, the ambitious revenue targets, the discrepancy in guaranteed payment figures, and the inherent risks associated with market adoption and patenting introduce significant uncertainty. While the agreement outlines potential for growth, it's contingent on future performance that is not guaranteed. A 'Hold' recommendation reflects the balance between potential upside and identified risks, advising investors to await further clarity on sales performance and resolution of financial discrepancies before making a more definitive move.

Keywords

Polomar Health Services, ForHumanity, distribution agreement, SEC filing, 8-K, product fulfillment, exclusivity, revenue milestones, guaranteed payments, dry inhalables, sildenafil, eletriptan, telemedicine, corporate governance, risk factors